title: Role of ranitidine in negative symptoms of schizophrenia--an open label study.
abstract: In this open label study, 75 patients with a diagnosis of schizophrenia were randomized to three groups of 25 each, receiving 150mg/day ranitidine, 300mg/day ranitidine and receiving only olanzapine. They were rated on PANSS at baseline, 4 and 8 weeks. There was a significant reduction in the scores of negative scale in patients receiving 300mg/day ranitidine in comparison to patients not receiving ranitidine at the end of 4 weeks but was not seen again when assessed at the end of 8 weeks. Though effective in reducing the negative symptoms, the effect was not sustained due to the tolerance to the actions of ranitidine.
authors.affiliation: Central Institute of Psychiatry, Kanke, Ranchi 834006, Jharkhand, India. Electronic address: vs_mehta@yahoo.co.in.
authors.forename: Varun S
authors.initials: VS
authors.lastname: Mehta
authors.affiliation: Central Institute of Psychiatry, Kanke, Ranchi 834006, Jharkhand, India. Electronic address: dram_cip@rediffmail.com.
authors.forename: Daya
authors.initials: D
authors.lastname: Ram
mesh_terms: D000328:Adult; D014150:Antipsychotic Agents / Q000627:therapeutic use*; D005260:Female; D006801:Humans; D008297:Male; D011899:Ranitidine / Q000627:therapeutic use*; D012559:Schizophrenia / Q000188:drug therapy*; D016896:Treatment Outcome; D055815:Young Adult
chemical_list: D014150:Antipsychotic Agents; D011899:Ranitidine
keywords: H2 blockers; Histamine; Negative symptoms